Lys52
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Mono-methylation Site Page: > Lys52  -  SLC25A4 (human)

Site Information
ISAEKQYkGIIDCVV   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 8107721
Available spectra:  2 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 )
Disease tissue studied:
esophageal cancer ( 19 , 20 ) , gastric cancer ( 15 ) , lung cancer ( 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 ) , non-small cell lung cancer ( 5 , 6 , 7 , 9 , 10 , 11 , 12 , 13 , 14 , 16 , 17 ) , non-small cell lung adenocarcinoma ( 5 , 6 , 8 , 9 , 10 , 11 , 13 ) , non-small cell large cell lung carcinoma ( 6 , 9 ) , non-small cell squamous cell lung carcinoma ( 8 , 17 ) , small-cell lung cancer ( 3 , 4 )
Relevant cell line - cell type - tissue:
A549 (pulmonary) ( 5 , 14 ) , Cal-12T (pulmonary) ( 10 ) , Calu-3 (pulmonary) ( 7 ) , DMS153 (pulmonary) ( 11 ) , DMS53 (pulmonary) ( 4 ) , DMS79 (pulmonary) ( 3 ) , esophagus ( 19 , 20 ) , HCC15 (pulmonary) ( 8 ) , HCC44 (pulmonary) ( 10 ) , HCC78 (pulmonary) ( 9 ) , HCC827 (pulmonary) ( 7 ) , HCT116 (intestinal) ( 2 , 18 ) , Jurkat (T lymphocyte) ( 21 , 22 , 23 ) , Kyse150 (esophageal) [SMYD2 (human), knockdown] ( 1 ) , Kyse150 (esophageal) ( 1 ) , LOU-NH91 (squamous) ( 8 ) , lung ( 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 ) , MKN-45 (gastric) ( 15 ) , NCI-H128 (pulmonary) ( 3 ) , NCI-H1299 (pulmonary) ( 6 ) , NCI-H1355 (pulmonary) ( 5 ) , NCI-H1417 (pulmonary) ( 3 ) , NCI-H1437 (pulmonary) ( 10 , 11 ) , NCI-H1650 (pulmonary) ( 7 ) , NCI-H1666 (pulmonary) ( 10 ) , NCI-H1703 (squamous) ( 8 , 17 ) , NCI-H1734 (pulmonary) ( 6 ) , NCI-H1781 (pulmonary) ( 9 ) , NCI-H1792 (pulmonary) ( 5 ) , NCI-H1944 (pulmonary) ( 6 ) , NCI-H1975 (pulmonary) ( 7 ) , NCI-H2073 (pulmonary) ( 8 , 11 ) , NCI-H209 (pulmonary) ( 3 , 11 ) , NCI-H2106 (pulmonary) ( 7 ) , NCI-H2228 (pulmonary) ( 9 , 13 ) , NCI-H23 (pulmonary) ( 5 ) , NCI-H2342 (pulmonary) ( 8 ) , NCI-H2405 (pulmonary) ( 10 ) , NCI-H3122 (pulmonary) ( 9 , 12 ) , NCI-H3255 (pulmonary) ( 16 ) , NCI-H358 (pulmonary) ( 6 ) , NCI-H441 (pulmonary) ( 5 ) , NCI-H446 (pulmonary) ( 4 ) , NCI-H460 (pulmonary) ( 6 ) , NCI-H524 (pulmonary) ( 3 ) , NCI-H526 (pulmonary) ( 4 ) , NCI-H661 (pulmonary) ( 9 ) , NCI-H69 (pulmonary) ( 4 ) , NCI-H82 (pulmonary) ( 4 ) , NCI-H838 (pulmonary) ( 11 )

References 

1

Olsen JB, et al. (2016) Quantitative Profiling of the Activity of Protein Lysine Methyltransferase SMYD2 Using SILAC-Based Proteomics. Mol Cell Proteomics 15, 892-905
26750096   Curated Info

2

Guo A, et al. (2014) Immunoaffinity enrichment and mass spectrometry analysis of protein methylation. Mol Cell Proteomics 13, 372-87
24129315   Curated Info

3

Rikova K (2013) CST Curation Set: 20125; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

4

Rikova K (2013) CST Curation Set: 20126; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

5

Rikova K (2013) CST Curation Set: 20127; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

6

Rikova K (2013) CST Curation Set: 20128; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

7

Rikova K (2013) CST Curation Set: 20129; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

8

Rikova K (2013) CST Curation Set: 20130; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

9

Rikova K (2013) CST Curation Set: 20131; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

10

Rikova K (2013) CST Curation Set: 20132; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

11

Rikova K (2013) CST Curation Set: 20133; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

12

Rikova K (2013) CST Curation Set: 18853; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

13

Rikova K (2013) CST Curation Set: 18852; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

14

Rikova K (2012) CST Curation Set: 16504; Year: 2012; Biosample/Treatment: cell line, A549/iressa, gleevec, crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

15

Rikova K (2012) CST Curation Set: 16501; Year: 2012; Biosample/Treatment: cell line, MKN45/crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

16

Rikova K (2012) CST Curation Set: 16502; Year: 2012; Biosample/Treatment: cell line, H3255/iressa; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

17

Rikova K (2012) CST Curation Set: 16503; Year: 2012; Biosample/Treatment: cell line, H1703/gleevec; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

18

Mulhern D (2012) CST Curation Set: 14368; Year: 2012; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

19

Tucker M (2010) CST Curation Set: 9898; Year: 2010; Biosample/Treatment: tissue, esophagus/untreated; Disease: esophageal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

20

Tucker M (2010) CST Curation Set: 9899; Year: 2010; Biosample/Treatment: tissue, esophagus/untreated; Disease: esophageal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

21

Possemato A (2009) CST Curation Set: 8354; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

22

Possemato A (2009) CST Curation Set: 8353; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

23

Possemato A (2008) CST Curation Set: 3776; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info